Spatial Acid-Associated Niches Inform Irinotecan-Based DEB-TACE in Colorectal Liver Metastases: A Multicentre Randomized Trial
In brief
UniPearls reached 100% disease control vs 69% with HepaSphere in a small trial
In a 35-patient randomized trial of unresectable colorectal liver metastases, disease control after the final irinotecan bead treatment was 100% with UniPearls versus 68.75% with HepaSphere among per-protocol patients. Objective response and adverse events were similar, and the apparent superiority depended on assumptions about missing outcomes, so larger studies are needed to confirm the benefit.
- Journal
- Liver international : official journal of the International Association for the Study of the Liver (Q1)
- Published
- 1 December 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Siyuan Weng, Wenwei Hu, Jianfei Tu, Junqing Xi, Hongbing Shi, Minhua Wu, et al.
- PMID
- 42969685
- DOI
- 10.1111/liv.70931
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (paper of the day, 5 November 2026): Randomized trial of acid‑targeted DEB‑TACE for colorectal liver metastases
Abstract
BACKGROUND & AIMS: Drug-eluting bead transarterial chemoembolisation (DEB-TACE), particularly irinotecan-based regimens, has emerged as a liver-directed option for unresectable colorectal liver metastases (CRLM), yet how metastatic-niche biology relates to local drug delivery remains poorly defined. METHODS: We integrated bulk, single-cell, and spatial transcriptomics with spatial pharmacogenomic inference (SpaDR) to characterize acid-associated states in CRLM and predict regional drug sensitivity, compared pH-dependent irinotecan release of UniPearls and HepaSphere microspheres, and evaluated both platforms in a four-centre randomised trial of 35 patients with unresectable CRLM. RESULTS: CRLM exhibited an acid-associated transcriptional phenotype (AcidScore), partly shared with TACE-nonresponder hepatocellular carcinoma and associated with shorter overall survival in CRLM. This phenotype localized to a spatially organized niche of SPP1+ macrophages and cancer-associated fibroblasts, in which AcidScore and malignant epithelium increased with distance from the vasculature, consistent with a putative stromal-metabolic barrier. SpaDR linked higher AcidScore to lower predicted SN-38 IC50 in most sections, identifying candidate sensitivity beyond this interface. Accordingly, UniPearls released more irinotecan than HepaSphere within 24 h at every pH tested, with the largest difference at pH 5.7. Disease control after the final DEB-TACE was higher with UniPearls (per-protocol, 100% vs. 68.75%; p = 0.018), as was final technical success (100% vs. 76.47%; p = 0.046); objective response and adverse-event frequencies were similar. Non-inferiority held across sensitivity analyses, whereas superiority was sensitive to missing-outcome assumptions. CONCLUSIONS: Acid-associated spatial organization and drug-response predictions provide a rationale for local irinotecan delivery in CRLM. These findings support further evaluation of UniPearls-based DEB-TACE and prospective biomarker-stratified studies linking niche biology to clinical benefit. TRIAL REGISTRATION: NCT06021015. Registered 27 August 2023, https://clinicaltrials.gov/study/NCT06021015.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.